TECHNOLOGY
46 are within the heart muscle , which means the mouse just isn ’ t predictive of how human hearts behave .”
That ’ s where this product , which works by synergising the developed tissues themselves with the types of electric impulses that you would see in a human heart , offers something new and unique to the market . Costa is absolutely convinced Novoheart can be a success , citing the fact the company is already working in conjunction with some of the global pharmaceutical giants as evidence .
“ I think this technology really has the potential to have a major disruptive impact on drug development ,” adds Costa . “ I think if we could shorten the amount of time that it takes to develop a drug to get approved , that would be a good thing .
“ If you ’ re going to invest in something , you need to have confidence that you ’ re investing in the things that are likely to bear fruit , and if they ’ re not going to work , then you want to know that as soon as possible so that you ’ re not wasting time and effort .”
Part of the reason for the $ 2-4bn figure mentioned above , says Costa , is that the cost is averaged out over such a low success rate . “ If we can increase
OCTOBER 2018